Primary cutaneous Aspergillus ustus infection: second reported case.
We describe the second case of primary cutaneous Aspergillus ustus infection in an immunocompromised patient. Cutaneous aspergillosis was confirmed both by culture and positive fluorescent antibody staining. Few species of Aspergillus are pathogenic in human beings, and fewer still cause primary cutaneous disease. The only other reported case of aspergillosis from Aspergillus ustus occurred in an immunosuppressed patient who was temporally and geographically separated from ours.
Ricci
R M
RM
Wilford Hall USAF Medical Center, Lackland AFB, Texas, USA.
Evans
J S
JS
Meffert
J J
JJ
Kaufman
L
L
Sadkowski
L C
LC
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy; D001230:Aspergillus / Q000145:classification* / Q000302:isolation & purification; D004396:Coloring Agents; D003881:Dermatomycoses / Q000175:diagnosis* / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D005455:Fluorescent Antibody Technique; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D017964:Itraconazole / Q000627:therapeutic use; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D004396:Coloring Agents; D005938:Glucocorticoids; D017964:Itraconazole; D011241:Prednisone